Flag of the European Union EU Clinical Trials Register Help

Clinical trials for West syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    219 result(s) found for: West syndrome. Displaying page 11 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11 
    EudraCT Number: 2013-000918-37 Sponsor Protocol Number: TRC112121 Start Date*: 2014-06-20
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high...
    Medical condition: Thrombocytopenic patients with myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) GR (Prematurely Ended) IE (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) ES (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-001778-21 Sponsor Protocol Number: A4001028 Start Date*: 2005-02-02
    Sponsor Name:PFIZER LTD
    Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006087-49 Sponsor Protocol Number: MEK115306 Start Date*: 2012-04-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjec...
    Medical condition: Cutaneous melanoma - aggressive form of skin cancers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040808 Skin cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001256-20 Sponsor Protocol Number: ITI 101724 Start Date*: 2005-11-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 375 ...
    Medical condition: Non-valvular Atrial Fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) EE (Completed) HU (Completed) DK (Completed) LV (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001336-62 Sponsor Protocol Number: 2019-ASPIREAF Start Date*: 2020-04-01
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial
    Medical condition: Perioperative atrial fibrillation after noncardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10042244 Stroke LLT
    20.0 100000004866 10005103 Bleeding LLT
    20.0 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002184-17 Sponsor Protocol Number: TRA115450 Start Date*: 2012-02-08
    Sponsor Name:Glaxosmithkline Research and Development Ltd
    Full Title: A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pa...
    Medical condition: To assess the efficacy of eltrombopag, relative to placebo, in achieving platelet counts of ≥ 50 Gi/L, when administered to pediatric subjects with previously treated chronic ITP during the first 1...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001266-15 Sponsor Protocol Number: BRF115532 Start Date*: 2013-02-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 muta...
    Medical condition: High-risk BRAF V600 mutation-positive melanoma after surgical resection.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DE (Completed) NO (Completed) GB (Completed) AT (Completed) GR (Completed) IT (Completed) NL (Completed) DK (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-001633-84 Sponsor Protocol Number: CFZ008 Start Date*: 2015-01-22
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphobla...
    Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10025230 Lymphatic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) FR (Completed) AT (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) GR (Completed) PL (Completed) PT (Completed) BG (Completed) NO (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000470-78 Sponsor Protocol Number: TRA102537 Start Date*: 2006-10-30
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe...
    Medical condition: Idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000550-21 Sponsor Protocol Number: 20170534 Start Date*: 2018-07-06
    Sponsor Name:Amgen Inc
    Full Title: Multicenter, Single-arm Open-label Extension Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta (OI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) CZ (Completed) FR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015106-19 Sponsor Protocol Number: MD7110852 Start Date*: 2009-12-07
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
    Medical condition: Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) SE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001402-92 Sponsor Protocol Number: AVA102670 Start Date*: 2006-09-06
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) BE (Completed) CZ (Completed) SI (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019547-19 Sponsor Protocol Number: AMB112529 Start Date*: 2010-07-16
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064911 Pulmonary arterial hypertension LLT
    12.1 10065150 Associated with pulmonary arterial hypertension LLT
    12.1 10065151 Idiopathic pulmonary arterial hypertension LLT
    12.1 10065152 Familial pulmonary arterial hypertension LLT
    12.1 10064911 Pulmonary arterial hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) NL (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003468-30 Sponsor Protocol Number: SAG/0211PFC-1131 Start Date*: 2014-09-24
    Sponsor Name:Sucampo Pharma Europe Ltd.
    Full Title: A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional...
    Medical condition: functional constipation in paediatric patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-002537-41 Sponsor Protocol Number: 20170104 Start Date*: 2022-01-06
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Sev...
    Medical condition: Moderate to Severe Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) RO (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001699-39 Sponsor Protocol Number: HER117158 Start Date*: 2015-03-11
    Sponsor Name:GlaxoSmithKline Research Development Ltd
    Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva...
    Medical condition: Subjects with advanced HER3-positive solid tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033575 Pancreas cancer LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001705-87 Sponsor Protocol Number: BRF117019 Start Date*: 2014-03-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and ...
    Medical condition: Mutations of BRAF V600E have been identified at a high frequency in melanoma, PTC, colorectal and ovarian cancers. Such mutations have also been reported in some rare cancers such as anaplastic t...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed) NL (Completed) ES (Ongoing) NO (Completed)
    Trial results: View results
    EudraCT Number: 2021-003477-61 Sponsor Protocol Number: 20210098 Start Date*: 2022-07-13
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Canc...
    Medical condition: Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    23.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084227 Gastroesophageal junction cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 15:42:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA